GPR133 Receptor Discovery: Key to Bone Strength Regulation and Osteoporosis Treatment

The Groundbreaking Discovery of GPR133 in Bone Regulation

A team of researchers from Leipzig University in Germany has uncovered a pivotal role for the adhesion G protein-coupled receptor GPR133, also known as ADGRD1, in maintaining bone strength. This orphan receptor, long overlooked, acts as a molecular switch that promotes bone formation by enhancing the activity of osteoblasts—the cells responsible for building new bone tissue—while indirectly suppressing osteoclasts, the cells that break down bone. 61 63 Published in Signal Transduction and Targeted Therapy on June 30, 2025, the study reveals how GPR133 responds to mechanical forces and cell-cell interactions, making it a promising target for combating age-related bone loss. 106

The discovery stems from genome-wide association studies linking GPR133 gene variants to bone mineral density variations in humans. In mice lacking the receptor, bones exhibited reduced density and strength early in life, mimicking human osteoporosis. This finding positions GPR133 as a central player in bone homeostasis, the delicate balance between formation and resorption essential for skeletal health.

Understanding Adhesion G Protein-Coupled Receptors (aGPCRs)

Adhesion G protein-coupled receptors (aGPCRs) are a unique family of 33 receptors in humans, characterized by large extracellular N-termini that mediate cell adhesion and large intracellular C-termini that transduce signals via G proteins. GPR133 belongs to this family, previously classified as an orphan receptor due to unknown natural ligands. Unlike classic GPCRs, aGPCRs undergo autoproteolysis, generating an N-terminal fragment (NTF) and C-terminal fragment (CTF), with the tethered 'Stachel' sequence on the CTF acting as an agonist. 63

In bone tissue, GPR133 is highly expressed in osteoblasts, where it integrates biophysical cues like stretch from physical activity and biochemical signals from protein tyrosine kinase 7 (PTK7), an endogenous ligand. This dual activation triggers intracellular cyclic AMP (cAMP) production, activating protein kinase A (PKA) and downstream β-catenin signaling, which drives osteoblast differentiation and matrix mineralization.

The Mechanism: From Mechanical Force to Bone Building

GPR133's mechanosensitivity is key. In vitro stretch assays on osteoblast-like MC3T3-E1 cells showed cyclic tensile strain (5-15%) increased cAMP only in wild-type cells, not GPR133 knockouts. Similarly, PTK7-coated surfaces mimicked this effect, confirming ligand-receptor interaction. 63 Downstream, elevated cAMP stabilizes β-catenin, upregulating osteogenic genes like Osx (Osterix), Alp (alkaline phosphatase), and Ocn (osteocalcin).

• Increased alkaline phosphatase activity and collagen deposition in treated cells.
• Enhanced mineralization, measured by Alizarin Red staining.
• Reduced osteoclastogenesis via elevated osteoprotegerin (OPG), inhibiting RANKL signaling.

A complementary study in Science Advances (July 2025) identified GL64, another agonist, that inhibits osteoclasts via cAMP-PKA-NFATc1 pathway, further supporting GPR133's dual role in bone remodeling. 62 107

AP503: The Novel Small Molecule Activator

AP503 (AP-970/43482503), discovered through computational screening, specifically activates GPR133 without off-target effects. In vitro, it dose-dependently raised cAMP in osteoblasts (1-1000 nM), boosting differentiation markers. In vivo, daily intraperitoneal injections (2 mg/kg for 4 weeks) in wild-type mice increased trabecular bone volume (BV/TV), bone mineral density (BMD), and strength, with synergy under mechanical loading like treadmill exercise. 61

In ovariectomized (OVX) mice modeling postmenopausal osteoporosis, AP503 restored cortical thickness, trabecular parameters, osteoblast numbers, and bone formation rate (BFR/BS), while reducing osteoclasts. Heterozygous mice showed intermediate benefits, suggesting therapeutic relevance for human genetic variants. For full details, see the open-access study. 106

Photo by Vitaly Gariev on Unsplash

Mouse Models Reveal Reversal of Bone Loss

Constitutive GPR133 knockouts displayed trabecularization of cortical bone, low BV/TV (reduced 30-50%), and brittle femurs/vertebrae via micro-CT and three-point bending tests. Histomorphometry confirmed fewer osteoblasts/osteocytes, lower BFR, and elevated resorption markers like CTX.

AP503 treatment normalized these, increasing osteoblast surfaces and serum P1NP (bone formation marker). No hypercalcemia risk, unlike some anabolic agents.

Osteoporosis Crisis in the United States

Osteoporosis affects over 10 million Americans, with 44 million more at risk (low bone mass), predominantly postmenopausal women (80%). Annually, it causes 2 million fractures, costing $22 billion in medical care, projected to rise to 3 million fractures by 2040. 78 Current treatments like bisphosphonates slow resorption but risk atypical fractures; anabolics like teriparatide are expensive and limited-duration. GPR133 activation offers dual action without these drawbacks. For NIH overview, visit NIAMS Osteoporosis page.

US Higher Education Leading Bone Research

While the GPR133 discovery originated at Leipzig University, US institutions like Harvard, Stanford, and Mayo Clinic dominate GPCR and bone biology research. NIH funds $200M+ annually for osteoporosis studies, fostering collaborations. US universities host GPCR consortia, training PhDs/postdocs in structural biology and pharmacology. This breakthrough spurs interdisciplinary work in mechanobiology and drug screening at labs like Scripps Research and Vanderbilt.

Future Outlook: From Bench to Bedside

AP503's preclinical success paves the way for Phase I trials, potentially by 2028. Challenges include human pharmacokinetics and long-term safety, but mouse reversals suggest efficacy in genetic or postmenopausal cases. Broader applications: spaceflight bone loss (NASA interest), sarcopenia. International patents pending; biotech firms eye commercialization. 108

Photo by Vitaly Gariev on Unsplash

• Genetic screening for GPR133 variants to identify at-risk patients.
• Combination with exercise for optimal mechanosignaling.
• Expansion to muscle wasting diseases.

Career Opportunities in Bone and GPCR Research

This discovery boosts demand for experts in aGPCRs, osteobiology, and computational drug design. US universities seek faculty in pharmacology, biomechanics; postdocs at NIH-funded centers; industry roles at Amgen, Eli Lilly developing bone therapeutics. Programs like /research-jobs offer openings in clinical trials and structural cryo-EM.

Stakeholder Perspectives and Challenges

Experts praise the dual osteoblast/osteoclast modulation, per Prof. Ines Liebscher: "GPR133 holds great potential for medical applications in aging." 61 Challenges: translating mouse efficacy, off-targets. Balanced views from Endocrine Society highlight need for diverse trials including men, minorities.